Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

BACKGROUND: Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor recepto...

Full description

Saved in:
Bibliographic Details
Published in:Trials
Main Authors: Ma, Cheng-Jen, Chang, Tsung-Kun, Tsai, Hsiang-Lin, Su, Wei-Chih, Huang, Ching-Wen, Yeh, Yung-Sung, Chang, Yu-Tang, Wang, Jaw-Yuan
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6923824/
https://ncbi.nlm.nih.gov/pubmed/31856912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-3917-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items